BostonGene partners with Mass. General Hospital’s Vaccine Immunotherapy Center

Jan. 16, 2020
BostonGene Corporation (BostonGene) announced its collaboration with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital. “Our collaboration with BostonGene is aimed at understanding the pathogenesis of each person’s cancer and ultimately having a positive impact on patient care by enabling personalized cancer treatments,” said Mark Poznansky, MD, PhD, at Massachusetts General Hospital.

BostonGene performs a computational analysis of a patient’s genomics and transcriptomics data from solid tumors including lung cancer and head and neck cancer. In parallel, MGH VIC team conducts mass cytometry analysis of tissue of same patients. A correlation analysis is then employed to demonstrate the power of the computational algorithms in the assessment of the intratumoral cellular composition including stromal and immune components. The results of this collaboration highlight the powerful advantage of NGS data analysis in comparison to conventional techniques to more fully characterize the tumor.

Using small amounts of tissue, BostonGene provides a patient-tailored report for physicians. The report includes a tumor schematics, called MF Portrait, depicting tumor activity, tumor cellular composition, activity of immune-microenvironment and other tumor-associated processes.

“BostonGene provides the solution necessary for oncologists to evaluate NGS data in combination with all relevant clinical knowledge to determine the best personalized care for the individual patient,” said Andrew Feinberg, President and CEO of BostonGene. “We are excited to collaborate with VIC at MGH to demonstrate how our unique solution for tailored treatment options improves outcomes for cancer patients.”

BostonGene has the announcement